Advertisement

Endoscopic Indices for Ulcerative Colitis

  • Taku KobayashiEmail author
Chapter

Abstract

Colonoscopy is a gold standard in assessing disease severity of ulcerative colitis, and therefore efforts have been made in order to quantify the severity of inflammation by endoscopic indices. Most indices have been proposed to assess the efficacy of clinical trials, and therefore not been validated. Baron score, ulcerative colitis endoscopic index of severity (UCEIS), and ulcerative colitis colonoscopic index of severity (UCCIS) are validated. There are some scoring systems in which different factors are graded for each item separately [Baron score, Rachmilewitz score, endoscopic activity index (EAI, UCEIS and UCCIS), and others grading multiple aspects altogether (Matts’ endoscopic grading, the Mayo endoscopic subscore (MES)]. It is essential to understand both strength and weakness of each index and utilize appropriately, since different indices have been developed for different purposes. It should be also noted that none of these widely used indices takes extent of inflammation into account. Currently, MES is most widely used in clinical trials for its simplicity, and UCEIS may become more common in the future because of its lower inter-observer variability. Definition of mucosal healing in each index has not been established yet.

Keywords

Ulcerative colitis Endoscopic index Mucosal healing 

References

  1. 1.
    Matts SG. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med. 1961;30:393–407.PubMedGoogle Scholar
  2. 2.
    Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J. 1964;1(5375):89–92.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk E, Borgen L. 5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92(6):1894–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–9. doi: 10.1056/NEJM198712243172603.CrossRefPubMedGoogle Scholar
  5. 5.
    Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298(6666):82–6.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Naganuma M, Ichikawa H, Inoue N, Kobayashi T, Okamoto S, Hisamatsu T, Kanai T, Ogata H, Iwao Y, Hibi T. Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. J Gastroenterol. 2010;45(9):936–43. doi: 10.1007/s00535-010-0244-2.CrossRefPubMedGoogle Scholar
  7. 7.
    Kobayashi T, Naganuma M, Okamoto S, Hisamatsu T, Inoue N, Ichikawa H, Takayama T, Saito R, Sujino T, Ogata H, Iwao Y, Hibi T. Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine a treatment for ulcerative colitis. J Gastroenterol. 2010;45(11):1129–37. doi: 10.1007/s00535-010-0273-x.CrossRefPubMedGoogle Scholar
  8. 8.
    Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lemann M, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Bernhardt CA, Mary JY, Sandborn WJ. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the ulcerative colitis endoscopic index of severity (UCEIS). Gut. 2012;61(4):535–42. doi: 10.1136/gutjnl-2011-300486.CrossRefPubMedGoogle Scholar
  9. 9.
    Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Schnell P, Bernhardt CA, Mary JY, Sandborn WJ. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013;145(5):987–95. doi: 10.1053/j.gastro.2013.07.024.CrossRefPubMedGoogle Scholar
  10. 10.
    Thia KT, Loftus Jr EV, Pardi DS, Kane SV, Faubion WA, Tremaine WJ, Schroeder KW, Harmsen SW, Zinsmeister AR, Sandborn WJ. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis. 2011;17(6):1257–64. doi: 10.1002/ibd.21480.CrossRefPubMedGoogle Scholar
  11. 11.
    Samuel S, Bruining DH, Loftus Jr EV, Thia KT, Schroeder KW, Tremaine WJ, Faubion WA, Kane SV, Pardi DS, de Groen PC, Harmsen WS, Zinsmeister AR, Sandborn WJ. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol. 2013;11(1):49–54. e41 doi: 10.1016/j.cgh.2012.08.003.CrossRefPubMedGoogle Scholar
  12. 12.
    Gower-Rousseau C, Dauchet L, Vernier-Massouille G, Tilloy E, Brazier F, Merle V, Dupas JL, Savoye G, Balde M, Marti R, Lerebours E, Cortot A, Salomez JL, Turck D, Colombel JF. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol. 2009;104(8):2080–8. doi: 10.1038/ajg.2009.177.CrossRefPubMedGoogle Scholar
  13. 13.
    Romberg-Camps MJ, Dagnelie PC, Kester AD, Hesselink-van de Kruijs MA, Cilissen M, Engels LG, Van Deursen C, Hameeteman WH, Wolters FL, Russel MG, Stockbrugger RW. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol. 2009;104(2):371–83. doi: 10.1038/ajg.2008.38.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2018

Authors and Affiliations

  1. 1.Center for Advanced IBD Research and TreatmentKitasato University Kitasato Insitiute HospitalTokyoJapan

Personalised recommendations